Cergentis news

Erik Splinter general manager Cergentis

A letter from Erik Splinter

| |
2 min read
Share

Celebrating achievements: a year-end reflection and anticipating 2024

 

As we approach the end of the year, I would like to take a moment to reflect on our accomplishments during 2023 and share some exciting developments for the coming year.

Back in 2021, we had the privilege of joining the NIST Genome Editing Consortium, an organization that brings together leading experts in genome editing across industry and academia. Early this year, we were proud to reveal the results of an Interlab Study, where our experts coupled TLA and ddPCR data to accurately determine lentiviral vector copy number (VCN) in 5 transgenic human cell lines. Having included VCN by ddPCR as part of our services this comparative study confirmed the quality and added value we bring to our customer projects. On this note, I am delighted to witness the ongoing recognition of our unmatched genetic insights, which are consistently highlighted in scientific literature. Noteworthily, our list of publications has expanded with 13 new papers this year, bringing the total to 109!

Secondly, we had the pleasure to collaborate with ATUM, a key US-based biotechnology player that provides tools and solutions for gene design, synthesis, protein and antibody services for cell line development. In a joint webinar we revealed how our experts quantified genetic stability and QC of orthogonal transposons in the generation of cell lines with Leap-In transposase® technology. A project and partnership to be proud of.

Furthermore, we have initiated a collaboration with BRC Biotechnology, an influential Chinese biosecurity testing service provider, who now acts as a trusted distributor of Cergentis’ genetic QC solutions in China. Complementing our existing partnership with Daon Biosciences, which provides accessibility to our services in South Korea the collaboration with BRC thereby plays a pivotal role in our Asia expansion.

One of our primary objectives in 2023 was to start the process of getting GMP certification. A critical step in running a high-quality facility. I am happy to share that we have made great strides in a short space of time and are well on track to deliver first services under GMP by Q3 2024. The efforts of the team accelerated by (1) the recruitment of highly experienced staff members and (2) by leveraging Solvias' two-decade-long expertise in delivering excellence in quality should not go unnoted.

Looking forward to 2024, I am thrilled to announce that Cergentis will become fully integrated into the Solvias brand. This marks another significant milestone in our journey. By becoming part of Solvias in 2022, a world leading CDMO/CRO, the ambition was to enhance the organization’s capabilities in biologics and gene therapy testing. Therefore, the decision to unify under one brand aligns perfectly with our shared mission and commitment to delivering exceptional integrated analytical solutions to our global customers for safer pharmaceuticals. Our team is excited to unveil our new branding in 2024 and looks forward to the possibilities it will bring.

Finally, I would like to share some words with the entire team that I am immensely proud of. Thank you all for your unwavering dedication to supporting our 614 customers, across 38 countries. Our achievements this year are a direct result of your commitment to delivering outstanding customer service, a driving force behind Cergentis' ongoing growth and success.

As we approach the holiday season, I extend my warmest wishes to our customers and partners for a healthy and joyful holiday season. Your trust and support mean the world to us, and we eagerly anticipate continuing to empower you in your mission to develop groundbreaking therapies for patients worldwide. Here's to a prosperous and exciting 2024!


Erik Splinter

General Manager, Cergentis

 

© 2012-2022 Cergentis B.V. All rights reserved.
For Research Use Only. Not for use in diagnostic procedures.